日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study

法国肿瘤早期临床试验机会不平等因素:EGALICAN-2 研究结果

Charton, E; Baldini, C; Fayet, Y; Schultz, E; Auroy, L; Vallier, E; Italiano, A; Robert, M; Coquan, E; Isambert, N; Moreau, P; Touzeau, C; Le Tourneau, C; Ghrieb, Z; Kiladjian, J-J; Delord, J-P; Gomez Roca, C; Vey, N; Barlesi, F; Lesimple, T; Penel, N; Soria, J-C; Massard, C; Besle, S

Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses' infections

新冠肺炎疫情对其他社区获得性呼吸道病毒感染抗病毒药物研发的影响

Ghrieb, Zineb; Salmona, Maud; Michonneau, David; De Saisset, Charles; Allaoua, Souhil; Kiladjian, Jean-Jacques; Le Goff, Jérôme; Bergeron, Anne; Benajiba, Lina

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

法国老年癌症患者参与早期临床试验的机会:EGALICAN-2 研究

Baldini, C; Charton, E; Schultz, E; Auroy, L; Italiano, A; Robert, M; Coquan, E; Isambert, N; Moreau, P; Le Gouill, S; Le Tourneau, C; Ghrieb, Z; Kiladjian, J J; Delord, J P; Roca, C Gomez; Vey, N; Barlesi, F; Lesimple, T; Penel, N; Soria, J C; Massard, C; Besle, S

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Ropeginterferon alpha-2b 在体内和体外靶向 JAK2V617F 阳性真性红细胞增多症细胞

Emmanuelle Verger, Juliette Soret-Dulphy, Nabih Maslah, Lydia Roy, Jerome Rey, Zineb Ghrieb, Robert Kralovics, Heinz Gisslinger, Barbara Grohmann-Izay, Christoph Klade, Christine Chomienne, Stéphane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian2